| HS Code | 871239 |
| Product Name | Infectious Laryngotracheitis Vaccine, Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Product Category | Veterinary Vaccine Active Pharmaceutical Ingredient |
| Vaccine Type | Live attenuated vaccine |
| Active Substance | Infectious Laryngotracheitis Virus (Gallid herpesvirus 1), live attenuated |
| Target Species | Chickens |
| Indication | Active immunization against infectious laryngotracheitis |
| Veterinary Grade | Yes |
| Intended Use | For manufacturing veterinary vaccine dosage forms |
| Compatible Dosage Forms | Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Route Of Administration | Ocular, nasal, drinking water, or spray depending on final formulation |
| Storage Conditions | Store at 2-8°C, protected from light |
| Quality Standard | Veterinary grade API for live vaccine production |
As an accredited Infectious Laryngotracheitis Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sterile, moisture-proof sealed vials, 100 g per unit, with temperature-controlled cold chain packaging for veterinary pharmaceutical use. |
| Container Loading (20′ FCL) | 20' FCL loading: temperature-controlled, secure stowage for live veterinary vaccine API, ensuring potency across tablets, powders, granules, and injection forms. |
| Shipping | Shipping of Infectious Laryngotracheitis Vaccine (live, veterinary grade API) requires strict cold-chain control, typically at 2–8°C, in insulated containers with gel packs. Ship as biological substance Category B, with proper labeling, temperature monitoring, and export/import permits to ensure viability and regulatory compliance. |
| Storage | Store between 2–8°C, protected from light and moisture. Do not freeze. Keep containers tightly sealed and stored in a dry, well-ventilated area. For live veterinary vaccine formulations, maintain cold chain integrity. Use aseptic handling during preparation or compounding to prevent contamination or inactivation before administration. |
| Shelf Life | Shelf life is typically 24 months when stored refrigerated at 2–8°C, protected from light, and not frozen. |
Downstream use of live infectious laryngotracheitis vaccine antigen is confined to veterinary biological formats that preserve tracheal-tropic infectivity through fill-finish, storage, and reconstitution. The application scenarios below are limited to those with published regulatory monographs and production-scale equipment data: lyophilised drinking-water powder, water-soluble granule premix, coarse-spray suspension, eye-drop solution, and origin-specific stabilisation before freeze-drying. Tablet, capsule, and injectable presentations are not established commercial downstream formats for this live herpesvirus antigen; injectable ILT products in autogenous programmes use inactivated virus, not live antigen.
Lyophilised drinking-water vaccine powder is processed as a stabilised plug rather than a dry-mix chemical powder. The release monograph for the live avian vaccine is 9 CFR 113.328 in the United States and Ph. Eur. monograph 1069 for European Pharmacopoeia markets; both require the final product to reconstitute within a defined interval, to contain no extraneous agents, and to demonstrate potency in susceptible chickens using WOAH Chapter 3.3.3 compendial methods. The working formulation addition ratio is 4:1 to 9:1 (w/w) stabiliser solution to clarified virus concentrate, where the stabiliser phase commonly contains 5.0% w/v sucrose, 2.0% w/v gelatin hydrolysate, and 0.1 M phosphate buffer at pH 7.0–7.4. The ratio is adjusted after potency titration so that each final container holds 103.0–104.0 EID50 per reconstituted drinking-water dose. Downstream production uses a jacketed 316L stainless steel blending vessel held at 2–8°C, a continuous-piston or peristaltic pump filling line, and a freeze-dryer with shelf temperature ramps from −45°C to +20°C over 36–72 h. During primary drying the product temperature is held below the collapse temperature of the stabilised matrix, commonly −28°C to −24°C for sucrose-rich formulations, and chamber vacuum is maintained at 500–1,500 μbar. Residual moisture is confirmed below 2.0% by Karl Fischer titration according to USP <921> Method Ic. Terminal finished-product types are Type I borosilicate vials containing a lyophilised plug for drinking-water administration; regional repackagers may convert freeze-dried material into water-soluble powder or granule sachets only when the stabiliser matrix provides measurable dry-flow protection without titre collapse.
Coarse spray is not a separate commercial formulation but a reconstituted aqueous suspension generated at the farm or hatchery from a lyophilised plug. The governing standards are the route-specific approval under 9 CFR 113.328 or Ph. Eur. monograph 1069, and droplet-size verification uses laser diffraction under ISO 13320:2020 with a wet dispersion cell. The target volume median diameter is 80–120 μm, which deposits vaccine on the conjunctiva and upper respiratory epithelium without producing deep-lung aerosol loss. The addition ratio is based on the approved diluent volume rather than a fixed excipient weight; one production-scale configuration uses 500 mL diluent per 1,000-dose vial and 1 L per 2,000-dose vial, producing a calculated post-reconstitution titre of 102.8–103.5 EID50 per 0.1 mL applied. Spray equipment in pullet grow-out houses includes positive-pressure cabinet atomisers and backpack or trolley systems with two-fluid nozzles; before reconstitution, chlorinated water must be treated with 0.1% w/v sodium thiosulfate because free chlorine above 0.5 ppm causes rapid titre loss. The terminal finished-product type is a single-use aqueous suspension administered immediately after mixing; it is not stored as a liquid because live ILT infectivity decays under field conditions at ambient temperature.
Eye-drop application forces a lower dose volume and stricter reconstitution accuracy than drinking-water delivery. The finished eye-drop suspension is prepared by dissolving the lyophilised plug in 30 mL or 100 mL of sterile diluent, and the calibrated dropper delivers 0.03 mL per bird. The target dose is 103.0–104.0 EID50 per 0.03 mL, confirmed by the same quantitative potency assay prescribed under 9 CFR 113.328 or Ph. Eur. monograph 1069. Reconstitution time, appearance, and microbial integrity of the liquid are tested under the same monograph; diluents cannot contain preservatives because phenolic or quaternary ammonium excipients inactivate live viral particles. Downstream packaging lines use a two-component format: a freeze-dried vial sealed with a dropper-tip closure or a polypropylene ampoule containing the reconstituted vaccine, plus a separate diluent bottle. Cold-chain storage at 2–8°C is required for both components, and the reconstituted solution is used within 2 h to prevent titre loss above 0.5 log10. Terminal finished-product types include single-dose dropper vials, dropper-tip ampoules, and dual-chamber mixing presentations intended for beak or eye administration in replacement pullets.
Water-soluble premix and granule formats expose live ILT antigen to ambient moisture and mechanical shear during dry-flow processing, so the formulation window is narrow. Compliance is governed by 9 CFR 113.328 or Ph. Eur. monograph 1069 for the live virus component, while powder-flow attributes are evaluated under USP <1174> and dynamic vapour sorption at 25°C and 40% RH; the water activity of the filled powder remains below 0.1 aw at release. The addition ratio of lyophilised antigen to carrier excipient ranges from 1:9 to 1:19 (w/w) when trehalose-maltodextrin carriers are used, but published data for specific commercial ILT granule premixes are limited, and each formulation must be justified by titre-retention studies rather than borrowed from chemical premix guidelines. Downstream production uses low-shear tumble blending at ≤6 rpm and jacketed temperature below 30°C; high-shear granulation is excluded because rotor-tip heating and added moisture routinely reduce infectivity by more than 1 log10. Terminal finished-product types include nitrogen-flushed powder sachets and granulated premix packs for small-poultry operations, though regulatory authorities in most markets still require the primary vaccine container to be a glass vial rather than a flexible sachet because live-virus stability depends on moisture-impermeable packaging and a desiccant pouch.
| Downstream format | Governing standard / method | Critical control parameter | Representative control window |
|---|---|---|---|
| Lyophilised drinking-water powder | 9 CFR 113.328; Ph. Eur. 1069 | Residual moisture after freeze-drying | <2.0% water by Karl Fischer |
| Coarse spray suspension | ISO 13320:2020; 9 CFR 113.328 | Droplet volume median diameter | 80–120 μm |
| Eye-drop solution | 9 CFR 113.328; Ph. Eur. 1069 | Delivered dose volume | 0.03 mL per bird |
| Water-soluble granule premix | USP <1174>; 9 CFR 113.328 | Powder water activity / flow | ≤0.1 aw at release |
Formulators must adjust stabiliser ratios and clarification steps when the live ILT antigen is produced in tissue-culture-origin cell substrates rather than chicken-embryo-origin allantoic fluid. The regulatory standard remains 9 CFR 113.328 or Ph. Eur. monograph 1069, with cell-substrate requirements under EU 2019/6 and extraneous-agent testing under WOAH Chapter 3.3.3; this route is selected when a more attenuated TCO antigen is required. For CEO allantoic harvests, the lower stabiliser-to-antigen range already described is generally employed, whereas serum-free TCO harvests require higher lyoprotectant mass, commonly 6:1 to 12:1 (w/w) stabiliser to antigen concentrate, because cell-derived protein is lower and virus is more sensitive to freeze-drying without serum proteins. Downstream clarification differs on the front end: CEO harvests are clarified by low-speed centrifugation and depth filtration, while TCO harvests are clarified by tangential-flow diafiltration with 100–300 kDa membranes to remove cell debris and spent serum-free media before blending and lyophilisation. One freeze-thaw cycle of TCO liquid harvest can reduce infectivity by 0.5–1.0 log10, so the bladder and filter train are maintained at 2–8°C with no intermediate frozen hold. Terminal finished-product types remain lyophilised powder for drinking-water, eye-drop, or spray administration, but the TCO formulation often produces a more porous cake and requires a longer reconstitution time; residual moisture and final titre limits remain the same as for CEO presentations.
Competitive Infectious Laryngotracheitis Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Infectious Laryngotracheitis Vaccine, Live Veterinary Grade API is a lyophilized live-virus intermediate derived from Gallid alphaherpesvirus 1 (GaHV-1) and intended solely for licensed veterinary biologic manufacturers producing finished immunologic dose forms across tablets, injections, capsules, powders, granules, premixes, and solutions. The API is not a finished trade product and is not labelled for direct on-farm administration. The live viral component is attenuated by serial passage in specific-pathogen-free embryonated chicken eggs or chicken cell culture, producing either a chicken-embryo-origin (CEO) or tissue-culture-origin (TCO) working seed. The manufacturer assigns model designation according to seed strain, passage level, stabilizer matrix, and bulk titre; a typical code may read ILT-LV-API/CEO or ILT-LV-API/TCO followed by the lot-specific passage number. The concentrated material is released against a specification that includes virus identity by neutralization or polymerase chain reaction, bacterial and fungal sterility, mycoplasma negativity, residual moisture, and virus titre in embryonated eggs or cell culture. The titre of the bulk intermediate is deliberately set above the intended finished-dose potency because blending, granulation, compression, lyophilization, reconstitution, and dilution each introduce process losses that must be compensated in the formulation. The API is supplied in glass vials or bulk freeze-dried trays under conditions that maintain the cold chain and protect the thermolabile enveloped virus from moisture and light.
The live GaHV-1 particle is an enveloped double-stranded DNA virus that is highly sensitive to drying stress, shear, osmolarity shifts, and pH below 6.0 or above 8.0. Bulk lyophilized API typically contains a protective matrix of sucrose, hydrolyzed gelatin, or skimmed milk; these stabilizers maintain infectivity during freezing and primary drying. Residual moisture in the lyophilized cake is controlled by Karl Fischer titration to ≤3.0% w/w according to USP <921> Method Ic. Higher residual moisture accelerates infectivity loss at storage temperatures above 2–8 °C. In tablet and capsule manufacturing, any wet granulation step must use pre-chilled granulating fluid, and the granulate must be dried in a fluid-bed dryer with inlet air temperature not exceeding 35 °C. In direct powder blending, the lyophilized API should be added after other excipients and mixed with low-shear tumble blending equipment rather than high-shear rotor–stator mixers. The prescribed virus titre after reconstitution is established by the finished product license and is commonly expressed as 104.0–105.0 EID50 or TCID50 per bird dose, depending on vaccination route. Bulk API concentrates may require a higher titre, often in the range of 106.0–107.0 TCID50/mL after reconstitution, to allow for dilution factors in premix and solution installations. Actual titres are assigned per manufacturer lot release protocol and are not transferable between dose forms without confirmatory titration.
Table 1. Product release specification matrix for the lyophilized live ILT API.
| Parameter | Acceptance criterion | Reference method |
|---|---|---|
| Virus identity | Positive for GaHV-1 | PCR or virus neutralization |
| Virus titre | Manufacturer assigned; finished target commonly 104.0 EID50 per dose; bulk concentrate 106.0–107.0 TCID50/mL | Embryonated egg titration or cell-culture titration |
| Sterility | No bacterial or fungal growth | 9 CFR 113.26 / Ph. Eur. 2.6.1 |
| Mycoplasma | Negative | Ph. Eur. 2.6.7 |
| Residual moisture | ≤3.0% w/w | USP <921> Method Ic |
| pH after reconstitution | 6.8–7.5 | Potentiometric determination |
| Appearance | White to off-white lyophilized cake; no collapse | Visual inspection |
The limiting variable in premix and solution processing is depletion of infectivity during contact with aqueous excipients. Once the lyophilized cake is rehydrated, the virus is immediately exposed to pH, oxidants, heavy metals, and temperature. Drinking-water vaccination requires chlorine-free water; residual free chlorine should be below 0.1 mg/L, and quaternary ammonium disinfectants must be absent from the line. Skimmed milk powder at 2.5 g/L or sodium thiosulfate at 0.1–0.2 g/L may be used to neutralize chlorine and stabilize the virus, but stabilizers must be qualified for use in the finished vaccine because excessive protein can foul spray nozzles or interfere with downstream mixing. The diluted vaccine should be delivered within 2 h when held at 20–25 °C or within 4 h when kept on ice. Exceeding these holding times does not render the vaccine sterile, but the viable titre may fall below the licensed minimum dose. In premix manufacturing, the API is often adsorbed onto a cold carrier such as lactose or dextrose before being dispersed into feed; direct mixing into warm feed above 40 °C is incompatible with the virus. Batch-to-batch variance in feed moisture and pH requires pre-qualification of each carrier lot because acidified premixes below pH 6.0 rapid inactivate the enveloped virion. Production-scale mixers should be tumble or ribbon blenders operated at low speed, and the API should not be passed through hammer mills or extruders that generate shear and frictional heat.
Injection-route processing for live ILT API does not begin with aqueous dissolution of the lyophilized cake at ambient temperature. The cake must be warmed to 2–8 °C before reconstitution with chilled diluent because rapid temperature shifts cause osmotic damage to the viral envelope. Reconstitution is performed in glass or polypropylene vessels; polystyrene surfaces may adsorb enveloped virus. If the finished product is an injectable suspension, the formulation must include a stabilizer that does not destabilize the virus during aseptic processing. However, sterile filtration through membranes with pore sizes below 0.45 µm is not recommended because viral aggregates can be retained. The injection route is not the most commonly licensed route for live ILT vaccines; most live ILT products are administered by eye drop, spray, or drinking water. Manufacturers considering an injectable form must generate safety and efficacy data because the live virus may establish infection after parenteral administration, and the resulting tissue distribution may differ from mucosal vaccination. Sterility assurance for injectable products follows veterinary parenteral requirements, but terminal heat or irradiation cannot be used; aseptic processing of the reconstituted live virus is mandatory. Holding time between reconstitution and filling should be minimized, and fill lines should be maintained at 2–8 °C. If the product is lyophilized in the final vial after aseptic filling, the stopper closure must allow adequate moisture removal without compromising container closure integrity.
Tablet and capsule presentations for live viral poultry vaccines are atypical and require specialized low-temperature solid dosage processing. Direct compression on a rotary tablet press with compaction pressures of 50–150 MPa is not generally compatible with the live GaHV-1 particle because compression shear and adiabatic heating may reduce infectivity; exact titre loss must be measured product-specifically because it depends on excipient cushioning and press settings. Manufacturers that pursue a tablet form should use freeze-dried or spray-dried excipient matrices that cushion the virus, and the active component is best incorporated as pre-formed lyophilized beads or granules rather than dry powder. If granulation is required, it should be performed by fluid-bed spray granulation with inlet air at 30–35 °C, and the granulate should be dried to residual moisture ≤3.0% w/w before compression. Tablets should be stored in desiccant-sealed blister packs under an inert atmosphere because ambient humidity above 60% RH rapidly rehydrates the cake and accelerates titre loss. Capsules are less destructive than tablets because filling can be accomplished without compaction; hard gelatin or hypromellose capsules may be filled with lyophilized beads under low-humidity conditions. For capsules, the fill weight must be controlled to ±5% or tighter, and filled capsules should be sealed with banding to prevent moisture ingress. The oral route for live ILT vaccination in solid dose forms has limited published efficacy data; therefore, any tablet or capsule claim must be supported by vaccination-challenge studies meeting the relevant veterinary biological licensing requirements. Enteric coating is not generally recommended because the live virus must contact respiratory lymphoid tissues rather than survive gastric transit; if oral delivery is intended, the dose form should be designed for buccal or sublingual dissolution rather than gastrointestinal absorption.
Live veterinary viral biologicals are released against a set of safety tests that include freedom from extraneous pathogenic viruses, bacteria, fungi, and mycoplasmas. For this API, identity and titre are assessed by inoculation of 9-day to 11-day-old embryonated chicken eggs via the chorioallantoic membrane, followed by observation for pock formation and embryo mortality. Cell-culture titration in primary chicken embryo kidney or chicken embryo liver cells may be used if the assay has been validated against egg titration. The finished live ILT vaccine must comply with the relevant European Pharmacopoeia monograph 1062 and with USDA 9 CFR requirements for avian live virus vaccines. Sterility testing is performed by membrane filtration or direct inoculation in accordance with Ph. Eur. 2.6.1; mycoplasma testing follows Ph. Eur. 2.6.7. The production seed lot is characterized for mycoplasma, avian leukosis virus, avian adenovirus, avian encephalomyelitis virus, and other extraneous agents specified in the marketing authorization. Titre release specifications are set as a minimum acceptable dose; a single lot that deviates by more than ±0.5 log10 from the expected titre after reconstitution should be investigated for lyophilization failure, cold-chain break, or diluent incompatibility. The live virus should be stored at −20 °C for long-term stability, but working stocks may be held at 2–8 °C for the period defined in the stability dossier. Repeated freeze–thaw cycles are not permitted because cycle-dependent titre loss is expected and is stabilizer-dependent.
Compared with inactivated ILT vaccines, this live API replicates in the upper respiratory tract and elicits mucosal and cell-mediated immune responses. Inactivated ILT vaccines do not replicate and generally require adjuvanted parenteral administration; they pose no reversion risk but may produce a different onset and duration of protection. The live ILT API carries the operational constraint of cold-chain maintenance and can be shed by vaccinated birds, which requires flock-level management. Compared with recombinant HVT-ILT or fowlpox-ILT vector vaccines, the live ILT antigen produces a direct homologous anti-ILT response but is not generally compatible with in ovo administration because of embryo mortality risks. Recombinant vectors can be administered in ovo or at day of hatch and are compatible with Marek’s disease vaccination programs, but the ILT-specific immune response may differ from that following live ILT vaccination. The live API can be blended into monovalent ILT vaccines or combined with Newcastle disease virus and infectious bronchitis virus live vaccines under specific compatibility protocols. Combination with killed or oily adjuvanted vaccines in the same primary container is not permitted unless the combined product has a specific marketing authorization.
Table 2. Comparative profiles of live ILT API, inactivated ILT antigen, and recombinant HVT-ILT vector.
| Attribute | Live ILT API | Inactivated ILT antigen | Recombinant HVT-ILT vector |
|---|---|---|---|
| Site of viral replication | Upper respiratory tract | No replication | Vector replication; limited ILT replication |
| Mucosal immune response | High local IgA and T-cell response | Limited mucosal component | Moderate ILT-specific mucosal response |
| Primary administration routes | Eye drop, spray, drinking water | Subcutaneous or intramuscular injection | In ovo or subcutaneous at hatch |
| Cold chain profile | Bulk frozen at −20 °C; diluted product at 2–8 °C | Liquid at 2–8 °C | Cell-associated stock at −196 °C or −80 °C |
| Reversion or latency risk | Possible, especially CEO strains | Not applicable | Low; vector restricted |
| Outbreak response speed | Rapid onset in respiratory tract | Slower onset relative to live virus | Intermediate; depends on vector replication |
When this API is used in powder or granule premises, the manufacturer must evaluate recovery of viable virus after vacuum drying, blending, and packaging. The primary packaging material should have a moisture vapour transmission rate below 0.1 g/m²/day at 38 °C and 90% RH for high-barrier protection. Desiccant loading is calculated from package headspace and expected storage duration. Incompatibilities include aldehydes, oxidizing disinfectants, cationic surfactants, and acidic excipients that lower local pH below 6.0. The live virus should not be combined with inactivated adjuvanted antigen in the same primary container unless explicitly authorized. Published data for the inclusion of live ILT API in compressed tablets or enteric-coated capsules is limited; manufacturers must generate product-specific stability data using the finished dose form under intended field conditions.
